Q: What is vorasidenib used for?

vorasidenib is used to treat IDH1- or IDH2- mutant diffuse glioma.

Q: How does vorasidenib work?

Targeting IDH Mutations Vorasidenib is designed to treat gliomas, a type of brain tumor, that have specific changes or mutations in genes called isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2). How the Medication Works In tumors with these mutations, the IDH enzymes become overactive and produce an abnormal chemical substance called 2-hydroxyglutarate (2-HG). High levels of 2-HG in the brain can interfere with normal cell function and promote the growth of cancer. Specifically, 2-HG: Encourages cancer cells to grow and divide more quickly. Prevents brain cells from maturing or developing as they should. Vorasidenib acts as an inhibitor, meaning it binds to the mutated IDH1 and IDH2 enzymes and blocks their activity. By stopping these enzymes from working, the medication reduces the production of 2-HG. This process helps to slow down the progression of the tumor and may help the cells behave more like normal, healthy cells.

Q: What are the active ingredients in vorasidenib?

The active ingredient in vorasidenib is vorasidenib .

Q: What are the side effects of vorasidenib?

Common side effects of vorasidenib may include: Fatigue Headache Nausea and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is vorasidenib?

vorasidenib belongs to the IDH inhibitor drug class.

Q: What is the dosage of vorasidenib and how do I take it?

How to Take Vorasidenib Vorasidenib is a tablet taken by mouth once a day. It must be taken on an empty stomach, which is defined as at least two hours before or one hour after a meal. Swallow the tablets whole with a glass of water. Do not crush, chew, or break the tablets. Missed Doses If you miss a dose, take it as soon as you remember on the same day. If you do not realize you missed the dose until the following day, skip the missed dose entirely and take your next dose at the regularly scheduled time. Do not take two doses at once to make up for a missed one. Vomiting If you vomit after taking a dose of vorasidenib, do not take an additional dose to replace it. Simply wait and take your next scheduled dose the following day at the usual time.

Q: Is vorasidenib safe during pregnancy and breastfeeding?

Pregnancy Based on its mechanism of action and findings from animal studies, vorasidenib can cause fetal harm when administered to a pregnant woman. There are no adequate studies on the use of this medication in humans during pregnancy. Individuals should inform their healthcare provider if they are pregnant or planning to become pregnant before starting treatment. Contraception Because of the potential risks to a fetus, healthcare providers typically recommend the following: Females: Use effective non-hormonal contraception during treatment and for 3 weeks after the final dose. Vorasidenib may interact with and decrease the effectiveness of hormonal contraceptives, such as birth control pills, patches, or injections. Males: Use effective contraception during treatment and for 3 weeks after the final dose if you have a female partner who could become pregnant. Breastfeeding It is not known if vorasidenib passes into human breast milk or if it could affect a nursing infant. Due to the risk of serious adverse reactions, it is advised that individuals do not breastfeed during treatment and for 2 months after the last dose of vorasidenib.

Q: What is the FDA approval status of vorasidenib?

FDA Approval Status The U.S. Food and Drug Administration (FDA) approved vorasidenib on August 6, 2024. It is marketed under the brand name Voranigo. This medication is indicated for adult and pediatric patients 12 years of age and older who have grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation. Vorasidenib is typically prescribed for patients who have already undergone surgery, such as a biopsy, subtotal resection, or gross total resection, to manage their condition. Regulatory Background The approval of vorasidenib was based on results from the INDIGO clinical trial, which demonstrated a significant improvement in progression-free survival compared to a placebo. This drug represents the first targeted therapy specifically approved for this patient population. At the time of approval, the FDA did not issue a Boxed Warning or require a Risk Evaluation and Mitigation Strategy (REMS) for this medication. However, healthcare providers must confirm the presence of IDH1 or IDH2 mutations using an FDA-approved companion diagnostic test before starting treatment.

Question 1

What is vorasidenib?

Accepted Answer

Vorasidenib is a type of medication known as an isocitrate dehydrogenase (IDH) inhibitor. It is designed to target and block the activity of mutated IDH1 and IDH2 enzymes. By interfering with these specific proteins, the medication helps to slow down or stop the progression of certain cancer cells.

This targeted approach focuses on the underlying genetic changes that drive the growth of the tumor. By inhibiting these enzymes, the drug aims to manage the disease at a molecular level.

Question 2

What is vorasidenib used for?

Accepted Answer

vorasidenib is used to treat IDH1- or IDH2-mutant diffuse glioma.

Question 3

How does vorasidenib work?

Accepted Answer

Targeting IDH Mutations

Vorasidenib is designed to treat gliomas, a type of brain tumor, that have specific changes or mutations in genes called isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2).

How the Medication Works

In tumors with these mutations, the IDH enzymes become overactive and produce an abnormal chemical substance called 2-hydroxyglutarate (2-HG). High levels of 2-HG in the brain can interfere with normal cell function and promote the growth of cancer. Specifically, 2-HG:

Encourages cancer cells to grow and divide more quickly.
Prevents brain cells from maturing or developing as they should.

Vorasidenib acts as an inhibitor, meaning it binds to the mutated IDH1 and IDH2 enzymes and blocks their activity. By stopping these enzymes from working, the medication reduces the production of 2-HG. This process helps to slow down the progression of the tumor and may help the cells behave more like normal, healthy cells.

Question 4

What are the active ingredients in vorasidenib?

Accepted Answer

The active ingredient in vorasidenib is vorasidenib.

Question 5

What are the side effects of vorasidenib?

Accepted Answer

Common side effects of vorasidenib may include:

Fatigue
Headache
Nausea
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is vorasidenib?

Accepted Answer

vorasidenib belongs to the IDH inhibitor drug class.

Question 7

What is the dosage of vorasidenib and how do I take it?

Accepted Answer

How to Take Vorasidenib

Vorasidenib is a tablet taken by mouth once a day. It must be taken on an empty stomach, which is defined as at least two hours before or one hour after a meal. Swallow the tablets whole with a glass of water. Do not crush, chew, or break the tablets.

Missed Doses

If you miss a dose, take it as soon as you remember on the same day. If you do not realize you missed the dose until the following day, skip the missed dose entirely and take your next dose at the regularly scheduled time. Do not take two doses at once to make up for a missed one.

Vomiting

If you vomit after taking a dose of vorasidenib, do not take an additional dose to replace it. Simply wait and take your next scheduled dose the following day at the usual time.

Question 8

Is vorasidenib safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Based on its mechanism of action and findings from animal studies, vorasidenib can cause fetal harm when administered to a pregnant woman. There are no adequate studies on the use of this medication in humans during pregnancy. Individuals should inform their healthcare provider if they are pregnant or planning to become pregnant before starting treatment.

Contraception

Because of the potential risks to a fetus, healthcare providers typically recommend the following:

Females: Use effective non-hormonal contraception during treatment and for 3 weeks after the final dose. Vorasidenib may interact with and decrease the effectiveness of hormonal contraceptives, such as birth control pills, patches, or injections.
Males: Use effective contraception during treatment and for 3 weeks after the final dose if you have a female partner who could become pregnant.

Breastfeeding

It is not known if vorasidenib passes into human breast milk or if it could affect a nursing infant. Due to the risk of serious adverse reactions, it is advised that individuals do not breastfeed during treatment and for 2 months after the last dose of vorasidenib.

Question 9

What forms and strengths does vorasidenib come in?

Accepted Answer

Vorasidenib is supplied as a tablet to be taken by mouth.

Question 10

What is the FDA approval status of vorasidenib?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved vorasidenib on August 6, 2024. It is marketed under the brand name Voranigo. This medication is indicated for adult and pediatric patients 12 years of age and older who have grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation.

Vorasidenib is typically prescribed for patients who have already undergone surgery, such as a biopsy, subtotal resection, or gross total resection, to manage their condition.

Regulatory Background

The approval of vorasidenib was based on results from the INDIGO clinical trial, which demonstrated a significant improvement in progression-free survival compared to a placebo. This drug represents the first targeted therapy specifically approved for this patient population.

At the time of approval, the FDA did not issue a Boxed Warning or require a Risk Evaluation and Mitigation Strategy (REMS) for this medication. However, healthcare providers must confirm the presence of IDH1 or IDH2 mutations using an FDA-approved companion diagnostic test before starting treatment.

Question 11

What should I know about vorasidenib and fda approval?

Accepted Answer

The U.S. Food and Drug Administration (FDA) approved vorasidenib on August 6, 2024. It is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma that have a susceptible IDH1 or IDH2 mutation.

This medication is intended for use following surgery, which may include a biopsy, subtotal resection, or gross total resection. Vorasidenib is the first targeted therapy specifically approved for patients with these types of low-grade gliomas.

The approval was based on results from the INDIGO Phase 3 clinical trial. This study demonstrated that vorasidenib significantly improved progression-free survival and delayed the time to the next treatment intervention compared to a placebo in patients with IDH-mutant Grade 2 gliomas.

Approval Date: August 6, 2024
Drug Class: Isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor
Indication: Post-surgical treatment for IDH-mutant Grade 2 gliomas

vorasidenib

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for vorasidenib

Hospitals.net Disclosure